Melanoma

Disease State Hub

Videos

Case Report Insights

Case Report Insights

Case Report Insights: Diagnosing Metastatic Malignant Melanoma From an Unknown Origin

07/15/2026

Nandini N. Patel, BS

In this Consultant Case Report Insights, Nandini N. Patel, OMS III, provides an overview of her study, “Metastatic Malignant Melanoma from Unknown Origin to the Jejunum: A Case Report.” In the video...

07/15/2026

Research Summaries

Conference Coverage

Conference Coverage

Intismeran Plus Pembrolizumab Shows Durable 5-Year Benefit in High-Risk Resected Melanoma

07/13/2026

Ashton L. Stahl

Updated 5-year data from KEYNOTE-942 showed that intismeran autogene plus pembrolizumab maintained durable recurrence-free and distant metastasis-free survival benefits in patients with high-risk resected...

07/13/2026

Research Summary

Research Summary

Adjuvant Pembrolizumab and Risk of New Skin Cancers in Stage IIB/IIC Melanoma: A Secondary Analysis of KEYNOTE-716

03/17/2026

Ashton L. Stahl

A secondary analysis of the phase 3 KEYNOTE-716 trial evaluates whether adjuvant pembrolizumab alters the risk of subsequent cutaneous malignancies in patients with resected stage IIB or IIC melanoma, while...

03/17/2026

Research Summary

Research Summary

COVID-19 mRNA Vaccines Linked to Better Outcomes with Immune Checkpoint Inhibitors in NSCLC and Melanoma

11/26/2025

Anthony Calabro, MA

For oncologists considering immunotherapy sequencing, a Nature report from MD Anderson Cancer Center in Houston, TX, suggests that receipt of a SARS-CoV-2 mRNA vaccine near the start of immune checkpoint...

11/26/2025

Research Summary

Do Long-Term Outcomes Support Combination Immunotherapy for Advanced Melanoma?

01/15/2025

Miranda Manier, BA

A decade-long follow-up of a landmark trial examining survival outcomes in patients with advanced melanoma treated with nivolumab plus ipilimumab, nivolumab monotherapy, or ipilimumab monotherapy, provides...

01/15/2025

Conference Coverage

Conference Coverage

Patients With Melanoma Using PD-1 Inhibitors Have Increased Risk of Adverse Autoimmune Neurologic Complications

05/31/2024

Jessica Ganga

Patients with melanoma and who are being treated with PD-1 inhibitors have an increased risk of experiencing immune-related neurologic adverse events, compared with patients who are not being treated with...

05/31/2024

July 2026

Current Issue

July 2026